| scholarly article | Q13442814 |
| P50 | author | David Johnson | Q37840488 |
| Philip Clarke | Q38590660 | ||
| Paolo Ferrari | Q43269545 | ||
| Carmel Hawley | Q46863719 | ||
| Sunil Badve | Q47145679 | ||
| Alan Cass | Q59553032 | ||
| Jeff S Coombes | Q60994552 | ||
| Donna Reidlinger | Q61650143 | ||
| Kim Dalziel | Q61650144 | ||
| P2093 | author name string | Lei Zhang | |
| Rowan Walker | |||
| Vlado Perkovic | |||
| Stephen P McDonald | |||
| Elaine M Pascoe | |||
| Eugenie Pedagogos | |||
| Liza A Vergara | |||
| Alicia T Morrish | |||
| Anish Scaria | |||
| On Behalf Of The Hero Study Collaborative Group | |||
| P2860 | cites work | Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? | Q27023641 |
| Superoxide dismutase-3 promotes full expression of the EPO response to hypoxia | Q28591239 | ||
| Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial | Q33356816 | ||
| Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines | Q34973977 | ||
| Prevalence of anemia in chronic kidney disease in the United States | Q35083495 | ||
| Oxidative stress in end-stage renal disease: an emerging threat to patient outcome | Q35155017 | ||
| Anaemia and inflammation: what are the implications for the nephrologist? | Q35579864 | ||
| Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified? | Q36218016 | ||
| Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. | Q36667201 | ||
| Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review | Q36679271 | ||
| Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia | Q37207365 | ||
| Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients | Q37422416 | ||
| Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis | Q37603998 | ||
| Elevated plasma F2-isoprostanes in patients on long-term hemodialysis | Q43586164 | ||
| Do different dialytic techniques have different atherosclerotic and antioxidant activities? | Q43749899 | ||
| Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure | Q44948985 | ||
| Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. | Q46006452 | ||
| Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. | Q46035400 | ||
| Influence of oxidative stress and inflammation on rHuEPO requirements of hemodialysis patients with CRP values "in normal range". | Q46843946 | ||
| A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial | Q48068592 | ||
| Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. | Q50521941 | ||
| Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. | Q51052485 | ||
| Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. | Q53532398 | ||
| Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes | Q57396250 | ||
| Determination of carbonyl content in oxidatively modified proteins | Q68161213 | ||
| Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients | Q73136889 | ||
| What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? | Q80554323 | ||
| KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target | Q80845843 | ||
| The influence of vitamin E supplementation on erythropoietin responsiveness in chronic hemodialysis patients with low levels of erythrocyte superoxide dismutase | Q83974875 | ||
| Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation | Q84576515 | ||
| Optimized method for quantification of total F(2)-isoprostanes using gas chromatography-tandem mass spectrometry | Q87015771 | ||
| Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients | Q87113230 | ||
| P433 | issue | 1 | |
| P921 | main subject | pentoxifylline | Q416331 |
| chronic renal insufficiency | Q736715 | ||
| erythropoiesis-stimulating agent | Q1363798 | ||
| P304 | page(s) | 14-23 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Redox Report | Q15758836 |
| P1476 | title | The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial | |
| P478 | volume | 21 |
| Q26775058 | The molecular mechanisms of hemodialysis vascular access failure | cites work | P2860 |
Search more.